Corcept Therapeutics Incorporated (CORT) is a publicly traded company in the Healthcare — Medical - Pharmaceuticals industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily.
Is Corcept Therapeutics Incorporated stock overvalued or undervalued in 2026?
Corcept Therapeutics Incorporated (CORT) trades at 64.5× earnings (P/E), above the median of the 249 healthcare companies over $2bn in Kaplio's universe. At the decade median (24.5×) $31 (-62 %); at its sector median (30.7×) $39 (-52 %).
Kaplio overview: Corcept Therapeutics Incorporated
Market cap $9B · 52 weeks $32 – $124 (35 % below the high) · P/E 64.5× · 2027 est. P/E 19.9× · Dividend none · Closing price, Nov 3 · accounts published Nov 3.
- Valuation: TTM P/E 64.5× (expensive).
- Business: ROIC 13 % (fair).
- Balance sheet: Net cash/EBITDA 5.4× (solid).
- Earnings: 3 of 8 (disappointing).
What would it be worth at its usual multiples?
At the decade median (24.5×) $31 (-62 %); at its sector median (30.7×) $39 (-52 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
P/E calculated by Kaplio with 12-month GAAP earnings; the data provider reports 54.6×.
What matters in pharma: 5 of 7 pass
- 5y EPS growth 0.9 %, fails.
- P/E vs own 10y history 64.5×, fails.
- R&D / Revenue 33.5 %, passes.
- Gross margin 98.3 %, passes.
- FCF / Net Income 142.3 %, passes.
- ROIC 12.9 %, passes, near the threshold.
- Net debt / EBITDA −5.4×, passes.
Against its peers (reference peers) — Corcept Therapeutics Incorporated: P/E 64.5×; EV/EBITDA 68.6×; ROIC 12.9 %; $8.9B. Kiniksa Pharmaceuticals International, plc (P/E 71.2×; EV/EBITDA 49.0×; ROIC 12.3 %; $7.3B), Liquidia Corporation (P/E 30.8×; EV/EBITDA 20.2×; ROIC 46.9 %; $3.8B), Royalty Pharma plc (P/E 38.2×; EV/EBITDA 22.0×; ROIC 9.0 %; $29.6B).
Expensive or cheap against its last 9 years?
P/E at each close: today 64.5× · median 24.6× · minimum 8.8× · maximum 96.3× · cheap below 21.6× · expensive above 42.5×. It has been cheaper than today 95% of the time over its last 9 years.
Profitability
| Return on Equity | 22.61% |
| Return on Invested Capital | 12.92% |
| Return on Assets | 15.45% |
| Gross Margin | 98.54% |
| Operating Margin | 11.51% |
| Net Margin | 16.57% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 3.00 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 14.11 |
Price Performance
| 1 month | -34.07% |
| 3 months | -25.47% |
| Year-to-date | +131.21% |
| 1 year | +13.16% |
| 3 years | +214.05% |
| 5 years | +289.07% |
| 10 years | +903.24% |
Related companies: MBX · RPRX · 0I3Q.L · KNSA · 0HF9.L · LQDA · PBH
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of CORT: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks